Terry W Moody

List of Publications by Year
in descending order

125 papers	7,658 citations	53794 45 h-index	54911 84 g-index
125 all docs	125 docs citations	125 times ranked	4190 citing authors

#	Article	IF	Citations
1	Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature, 1985, 316, 823-826.	27.8	1,337
2	Adrenomedullin Expression in Human Tumor Cell Lines ITS POTENTIAL ROLE AS AN AUTOCRINE GROWTH FACTOR. Journal of Biological Chemistry, 1996, 271, 23345-23351.	3.4	274
3	Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene, 2004, 23, 6170-6174.	5.9	248
4	Autoradiographic distribution of substance P receptors in rat central nervous system. Nature, 1983, 303, 714-716.	27.8	231
5	I. High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sciences, 1985, 37, 105-113.	4.3	231
6	Fiveâ€lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB Journal, 2001, 15, 2007-2009.	0.5	181
7	Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 58-64.	2.3	179
8	Bombesin: Receptor distribution in brain and effects on nociception and locomotor activity. Brain Research, 1980, 193, 209-220.	2.2	170
9	Bombesin-like peptides in rat brain: Quantitation and biochemical characterization. Biochemical and Biophysical Research Communications, 1979, 90, 7-14.	2.1	150
10	HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Research, 1993, 603, 222-233.	2.2	130
11	Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current Status. Current Drug Delivery, 2011, 8, 79-134.	1.6	128
12	Expression of Adrenomedullin and Its Receptor in Normal and Malignant Human Skin: A Potential Pluripotent Role in the Integument. Endocrinology, 1997, 138, 5597-5604.	2.8	120
13	Bombesin-like peptides and associated receptors within the brain: distribution and behavioral implications. Peptides, 2004, 25, 511-520.	2.4	112
14	Neuropeptides as Autocrine Growth Factors in Cancer Cells. Current Pharmaceutical Design, 2003, 9, 495-509.	1.9	110
15	Alterations in rat central nervous system endorphins following transauricular electroacupuncture. Brain Research, 1981, 224, 83-93.	2.2	107
16	The Effects of Adrenomedullin Overexpression in Breast Tumor Cells. Journal of the National Cancer Institute, 2002, 94, 1226-1237.	6.3	103
17	Bombesin-like peptides and receptors in human tumor cell lines. Peptides, 1983, 4, 683-686.	2.4	98
18	VIP as a trophic factor in the CNS and cancer cells. Peptides, 2003, 24, 163-177.	2.4	93

#	Article	IF	Citations
19	Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opinion on Therapeutic Targets, 2016, 20, 1055-1073.	3.4	92
20	Insights into bombesin receptors and ligands: Highlighting recent advances. Peptides, 2015, 72, 128-144.	2.4	90
21	Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 38-47.	2.3	89
22	Bombesin-like peptides in rat brain: Localization in synaptosomes and release from hypothalamic slices. Life Sciences, 1980, 26, 1707-1712.	4.3	88
23	Growth factor and peptide receptors in small cell lung cancer. Life Sciences, 1993, 52, 1161-1173.	4.3	83
24	VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies. Current Opinion in Endocrinology, Diabetes and Obesity, 2011, 18, 61-67.	2.3	82
25	Autoradiographic visualization of CNS receptors for vasoactive intestinal peptide. Peptides, 1986, 7, 283-288.	2.4	78
26	Distribution of bombesin binding sites in the rat gastrointestinal tract. Peptides, 1988, 9, 643-649.	2.4	76
27	Detection of adrenomedullin, a hypotensive peptide, in amniotic fluid and fetal membranes. American Journal of Obstetrics and Gynecology, 1996, 175, 906-911.	1.3	75
28	Development of High Affinity Camptothecin-Bombesin Conjugates That Have Targeted Cytotoxicity for Bombesin Receptor-containing Tumor Cells. Journal of Biological Chemistry, 2004, 279, 23580-23589.	3.4	73
29	Bombesin-like peptides in small cell lung cancer: Biochemical characterization and secretion from a cell line. Life Sciences, 1983, 32, 487-493.	4.3	71
30	Bombesin-like peptides elevate cytosolic calcium in small cell lung cancer cells. Biochemical and Biophysical Research Communications, 1987, 147, 189-195.	2.1	69
31	Bombesin-like peptides in rat spinal cord: Biochemical characterization, localization and mechanism of release. Life Sciences, 1981, 29, 2273-2279.	4.3	66
32	Distribution and origin of bombesin, substance P and somatostatin in cat spinal cord. Peptides, 1983, 4, 673-681.	2.4	66
33	Increased Expression of Insulin-Like Growth Factor I and/or Its Receptor in Gastrinomas Is Associated with Low Curability, Increased Growth, and Development of Metastases. Clinical Cancer Research, 2005, 11, 3233-3242.	7.0	66
34	Biochemical characterization and autoradiographic localization of central substance P receptors using [125I]physalaemin. Brain Research, 1985, 332, 299-307.	2.2	63
35	Biochemical and histochemical characterization of ranatensin immunoreactive peptides in rat brain: Lack of coexistence with bombesin/GRP. Brain Research, 1985, 338, 97-113.	2.2	57
36	Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo. Oncogene, 2005, 24, 4106-4113.	5.9	55

#	Article	IF	Citations
37	The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. International Journal of Biological Sciences, 2016, 12, 283-291.	6.4	53
38	Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer, 2001, 31, 203-212.	2.0	52
39	Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. European Journal of Pharmacology, 2010, 637, 38-45.	3.5	51
40	SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides, 2001, 22, 109-115.	2.4	50
41	In Vitro and in Vivo Antitumor Effects of Cytotoxic Camptothecin-Bombesin Conjugates Are Mediated by Specific Interaction with Cellular Bombesin Receptors. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1265-1272.	2.5	50
42	Neurotensin is produced by and secreted from classic small cell lung cancer cells. Life Sciences, 1985, 36, 1727-1732.	4.3	49
43	Autoradiographic visualization of rat brain binding sites for bombesin-like peptides. European Journal of Pharmacology, 1983, 87, 163-164.	3.5	48
44	High affinity binding of cholecystokinin to small cell lung cancer cells. Peptides, 1987, 8, 103-107.	2.4	48
45	VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Research and Treatment, 2001, 68, 55-64.	2.5	47
46	Sigma receptors are expressed in human non-small cell lung carcinoma. Life Sciences, 1995, 56, 2385-2392.	4.3	46
47	High affinity binding of VIP to human lung cancer cell lines. Peptides, 1987, 8, 1101-1106.	2.4	45
48	Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells. Peptides, 1993, 14, 241-246.	2.4	45
49	Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer. Current Pharmaceutical Design, 2007, 13, 1099-1104.	1.9	45
50	Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors. Peptides, 2009, 30, 1473-1486.	2.4	43
51	Neuropeptide G Protein-Coupled Receptors as Oncotargets. Frontiers in Endocrinology, 2018, 9, 345.	3.5	43
52	Monoclonal antibody Î±IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. Journal of Cellular Biochemistry, 1996, 63, 269-275.	2.6	42
53	Pituitary Adenylate Cyclase-Activating Polypeptide Causes Tyrosine Phosphorylation of the Epidermal Growth Factor Receptor in Lung Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 873-881.	2.5	42
54	(Arg15, Arg21) VIP: Evaluation of Biological Activity and Localization to Breast Cancer Tumors. Peptides, 1998, 19, 585-592.	2.4	41

#	Article	IF	Citations
55	A structureâ€"function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists. Peptides, 2015, 66, 26-42.	2.4	41
56	Expression of Adrenomedullin and Its Receptor in Normal and Malignant Human Skin: A Potential Pluripotent Role in the Integument. Endocrinology, 1997, 138, 5597-5604.	2.8	39
57	Neuromedin B-like peptides in rat brain: Biochemical characterization, mechanism of release and localization in synaptosomes. Peptides, 1986, 7, 815-820.	2.4	38
58	Substance P analogues function as bombesin receptor antagonists and inhibit small cell lung cancer clonal growth. Peptides, 1988, 9, 1367-1372.	2.4	38
59	Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. European Journal of Pharmacology, 2003, 474, 21-29.	3.5	38
60	Cholecystokinin elevates cytosolic calcium in small cell lung cancer cells. Biochemical and Biophysical Research Communications, 1989, 163, 605-610.	2.1	37
61	PACAP (6â€"38) is a PACAP receptor antagonist for breast cancer cells. Breast Cancer Research and Treatment, 1999, 56, 175-184.	2.5	37
62	Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. Lung Cancer, 2010, 68, 154-160.	2.0	35
63	Peptides and growth factors in non-small cell lung cancer. Peptides, 1996, 17, 545-555.	2.4	34
64	A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer, 2001, 92, 2172-2180.	4.1	33
65	EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer. Current Drug Targets, 2016, 17, 520-528.	2.1	33
66	Neurotensin binds with high affinity to small cell lung cancer cells. Peptides, 1988, 9, 57-61.	2.4	31
67	Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation. Peptides, 2011, 32, 1677-1684.	2.4	31
68	Neurotensin elevates cytosolic calcium in small cell lung cancer cells. Peptides, 1989, 10, 1217-1221.	2.4	30
69	VIP-ellipticine derivatives inhibit the growth of breast cancer cells. Life Sciences, 2002, 71, 1005-1014.	4.3	29
70	CCK antagonists interact with CCK-B receptors on human small cell lung cancer cells. Peptides, 1990, 11, 1033-1036.	2.4	28
71	Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells. European Journal of Pharmacology, 2002, 442, 179-186.	3.5	28
72	Autoradiographic localization of neuromedin B binding sites in rat brain. Molecular and Cellular Neurosciences, 1990, 1, 161-167.	2.2	27

#	Article	IF	Citations
73	Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells. European Journal of Pharmacology, 2000, 409, 133-142.	3.5	27
74	A bombesin receptor subtype-3 peptide increases nuclear oncogene expression in a MEK-1 dependent manner in human lung cancer cells. European Journal of Pharmacology, 2001, 412, 13-20.	3.5	27
75	PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells. Regulatory Peptides, 2002, 109, 135-140.	1.9	27
76	CAI inhibits the growth of small cell lung cancer cells. Lung Cancer, 2003, 39, 279-288.	2.0	27
77	Thymosin Î±1 as a Chemopreventive Agent in Lung and Breast Cancer. Annals of the New York Academy of Sciences, 2007, 1112, 297-304.	3.8	27
78	Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells. Cancer Letters, 2001, 162, 87-95.	7.2	26
79	A Vasoactive Intestinal Peptide Antagonist Inhibits the Growth of Glioblastoma Cells. Journal of Molecular Neuroscience, 2001, 17, 331-340.	2.3	26
80	BW2258U89: A GRP receptor antagonist which inhibits small cell lung cancer growth. Life Sciences, 1995, 56, 521-529.	4.3	25
81	Bombesin activates MAP kinase in non-small cell lung cancer cells. Peptides, 1999, 20, 121-126.	2.4	25
82	SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner. Life Sciences, 2014, 100, 25-34.	4.3	25
83	A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3. Peptides, 2018, 101, 213-226.	2.4	25
84	Thymosin Î±1 inhibits mammary carcinogenesis in Fisher rats. Peptides, 2002, 23, 1011-1014.	2.4	24
85	Reduction in transforming growth factor-Î² type II receptor in mouse lung carcinogenesis. Molecular Carcinogenesis, 1998, 22, 46-56.	2.7	23
86	(N-stearyl, Norleucine¹⁷)VIPhybrid is a Broad Spectrum Vasoactive Intestinal Peptide Receptor Antagonist. Journal of Molecular Neuroscience, 2002, 18, 29-36.	2.3	23
87	VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice. Life Sciences, 2004, 74, 1345-1357.	4.3	23
88	Vasoactive intestinal peptideâ€“camptothecin conjugates inhibit the proliferation of breast cancer cells. Peptides, 2007, 28, 1883-1890.	2.4	23
89	Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): Affinities, potencies and selectivity in multiple native and BnR transfected cells. Peptides, 2010, 31, 1569-1578.	2.4	23
90	Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells. Peptides, 2017, 90, 90-99.	2.4	23

#	Article	IF	Citations
91	Enhanced tumorigenesis and reduced transforming growth factor-? type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-?1. Molecular Carcinogenesis, 2000, 29, 112-126.	2.7	22
92	Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells. Peptides, 2005, 26, 1560-1566.	2.4	22
93	TGFÎ±-PE40 inhibits non-small cell lung cancer growth. Life Sciences, 1994, 54, 445-453.	4.3	21
94	ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth. Peptides, 2015, 64, 55-61.	2.4	21
95	Bombesin/Gastrin-Releasing Peptide Receptor Antagonists Increase the Ability of Histone Deacetylase Inhibitors to Reduce Lung Cancer Proliferation. Journal of Molecular Neuroscience, 2006, 28, 231-238.	2.3	20
96	ThymosinÎ±1 is chemopreventive for lung adenoma formation in A/J mice. Cancer Letters, 2000, 155, 121-127.	7.2	19
97	Neuropeptides as lung cancer growth factors. Peptides, 2015, 72, 106-111.	2.4	19
98	Bombesin marine toxin conjugates inhibit the growth of lung cancer cells. Life Sciences, 2008, 82, 855-861.	4.3	18
99	Somatostatin inhibits the secretion of bombesin-like peptides from small cell lung cancer cells. Peptides, 1988, 9, 257-261.	2.4	17
100	AH6809 antagonizes non-small cell lung cancer prostaglandin receptors. Lung Cancer, 2002, 36, 33-42.	2.0	17
101	Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy. Frontiers in Endocrinology, 2021, 12, 728088.	3.5	17
102	Transforming Growth Factor-Beta Expression in Mouse Lung Carcinogenesis. Experimental Lung Research, 1998, 24, 579-593.	1.2	16
103	The G Proteinâ€"Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3. Journal of Molecular Neuroscience, 2021, 71, 1589-1597.	2.3	16
104	The development of VIPâ€"ellipticine conjugates. Regulatory Peptides, 2004, 123, 187-192.	1.9	15
105	Breast Cancer VPAC1 Receptors. Annals of the New York Academy of Sciences, 2006, 1070, 436-439.	3.8	15
106	Bombesin-Related Peptides and Neurotensin: Effects on Cancer Growth/Proliferation and Cellular Signaling in Cancer. , 2006, , 429-434.		14
107	Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 198-205.	2.3	14
108	CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells. Journal of Molecular Neuroscience, 2015, 56, 663-672.	2.3	13

#	Article	IF	Citations
109	Peptide receptors as cancer drug targets. Annals of the New York Academy of Sciences, 2019, 1455, 141-148.	3.8	13
110	Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118625.	4.1	13
111	PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner. Peptides, 2019, 120, 170017.	2.4	11
112	Bombesin/GRP and vasoactive intestinal peptide/PACAP as growth factors. Growth Factors and Cytokines in Health and Disease, 1996, 1, 491-535.	0.2	10
113	Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner. European Journal of Pharmacology, 2019, 865, 172735.	3.5	8
114	Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 206-213.	2.3	8
115	PYK-2 is Tyrosine Phosphorylated after Activation of Pituitary Adenylate Cyclase Activating Polypeptide Receptors in Lung Cancer Cells. Journal of Molecular Neuroscience, 2012, 48, 660-666.	2.3	7
116	PACAP and Cancer. Current Topics in Neurotoxicity, 2016, , 795-814.	0.4	7
117	Pituitary Adenylate Cyclase-Activating Polypeptide Causes Increased Tyrosine Phosphorylation of Focal Adhesion Kinase and Paxillin. Journal of Molecular Neuroscience, 2012, 46, 68-74.	2.3	6
118	Bombesin, endothelin, neurotensin and pituitary adenylate cyclase activating polypeptide cause tyrosine phosphorylation of receptor tyrosine kinases. Peptides, 2021, 137, 170480.	2.4	6
119	Bombesin Peptides. , 2013, , 506-511.		5
120	AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists. Frontiers in Endocrinology, 2017, 8, 176.	3.5	4
121	Bombesin-Related Peptides. , 2013, , 1188-1196.		3
122	VIP and PACAP as Autocrine Growth Factors in Breast and Lung Cancer. , 2006, , 473-477.		2
123	VIP/PACAP Receptors. , 2013, , 556-561.		2
124	ADCYAP1 (adenylate cyclase activating polypeptide 1 (pituitary)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2017, , .	0.1	0
125	Cancer Cell Receptor Internalization and Proliferation: Effects of Neuropeptide Analogs. Neuromethods, 2008, , 115-129.	0.3	0